Last reviewed · How we verify

Bupivacaine %0.25 (isobaric)

Bursa City Hospital · FDA-approved active Small molecule

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local and regional anesthesia for surgical procedures, Spinal anesthesia, Epidural anesthesia.

At a glance

Generic nameBupivacaine %0.25 (isobaric)
Also known asPlain bupivacaine
SponsorBursa City Hospital
Drug classLocal anesthetic (amide class)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, inhibiting sodium influx and preventing depolarization. This action halts the generation and conduction of nerve impulses in the area where it is administered. The isobaric formulation (0.25%) has a specific gravity equal to cerebrospinal fluid, making it suitable for spinal anesthesia with minimal positional effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: